Greenleaf: Most Republicans View Kennedy as Qualified to Lead HHS
Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.
After the hearings in which Senators from the Finance Committee quizzed Robert F. Kennedy Jr., the HHS secretary nominee, but before this week’s committee vote, Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, spoked with Managed Healthcare Executive about what Kennedy’s confirmation could mean for HHS, Medicare and Medicaid, and the Inflation Reduction Act.
Greenleaf said the despite Kennedy’s gaps in knowledge about Medicare and Medicaid and his controversial views about vaccine, he still has a good chance of being confirmed by the full Senate.
“Most Republicans would view [Kennedy] as being qualified, and his background and an attorney as fighting these issues that are so focused on healthcare, the way he has shaped this Make America healthy again movement. This is who President Trump wants to put in place for this position, so seems like his chances are pretty good of getting confirmed,” she said. “It would take a lot [for Republican senators] to want to go against the president.”
Regarding Medicare and Medicaid, Greenleaf suggested that Kennedy, if confirmed, would likely rely on people overseeing these programs, at least initially.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More
